Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues

CellCarta’s poster highlights the development and validation of multiplexed MRM assays for precise quantitation of clinically relevant biomarkers in FFPE tissue.

The study demonstrates the feasibility of using these assays for clinical proteomics, supporting patient stratification, treatment optimization, and drug resistance prediction. The 12-plex biomarker panel includes key proteins such as HER2, EGFR, and CEACAM5, validated to CPTAC guidelines.

The approach is suitable for GCLP-compliant quantitative clinical analysis, providing robust and reliable biomarker measurements to aid in the clinical development of novel therapies.

Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues,

As presented in SITC 2020